Assessing direct costs of treating metastatic triple-negative breast cancer in the USA

被引:13
|
作者
Skinner, Karen E. [1 ]
Haiderali, Amin [2 ]
Huang, Min [2 ]
Schwartzberg, Lee S. [3 ]
机构
[1] Vector Oncol, 6555 Quince,Suite 400, Memphis, TN 38119 USA
[2] Merck & Co Inc, 351 N Sumneytown Pike, N Wales, PA 19454 USA
[3] West Canc Ctr, 7945 Wolf Rive Blvd, Germantown, TN 38138 USA
关键词
disease progression; healthcare costs; health expenditures; retrospective studies; triple-negative breast neoplasms; UNITED-STATES; SURVIVAL; WOMEN; PATTERNS; FEATURES; OUTCOMES; THERAPY;
D O I
10.2217/cer-2020-0213
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Aim: Evaluation of monthly cost during metastatic triple-negative breast cancer (mTNBC) treatment. Patients & methods: Retrospective electronic medical record review of US females aged >= 18 years diagnosed with mTNBC between 1 January 2010 and 31 January 2016. Mean monthly costs per patient were evaluated from start of mTNBC treatment until transfer to hospice, end of record or 3 months prior to death. Results: The mean monthly cost of first line was $21,908 for 505 treated patients; 50.2% of cost was attributable to hospitalization and emergency department visits, and 32.7% to anticancer therapy. Similar patterns were observed for subsequent lines of therapy. Conclusion: The majority of costs were attributable to hospitalization and emergency department services, suggesting a need for effective interventions to reduce utilization of costly services. Lay abstract This study looked at monthly cost during metastatic triple-negative breast cancer (mTNBC) treatment. Medical records were reviewed for US females aged 18 years or older, diagnosed with mTNBC between January 2010 and January 2016. Average monthly costs per patient were looked at from the start of mTNBC treatment until transfer to end of life care, end of the medical record or 3 months before death. The average monthly cost of first-line treatment was $21,908 for 505 treated patients; about half of this cost was from hospitalization and emergency department visits, and about a third was from anticancer therapy. Similar patterns were seen for subsequent lines of therapy. Most of the costs were from hospitalization and emergency department services, pointing to a need for change to reduce the use of costly services.
引用
收藏
页码:109 / 118
页数:10
相关论文
共 50 条
  • [2] Metastatic Triple-negative Breast Cancer
    Rakha, E. A.
    Chan, S.
    CLINICAL ONCOLOGY, 2011, 23 (09) : 587 - 600
  • [3] Metastatic Triple-Negative Breast Cancer
    Zhang, Xiaojie
    Yeung, Kay T.
    CURRENT BREAST CANCER REPORTS, 2023, 15 (03) : 288 - 297
  • [4] Metastatic Triple-Negative Breast Cancer
    Xiaojie Zhang
    Kay T. Yeung
    Current Breast Cancer Reports, 2023, 15 : 288 - 297
  • [5] Understanding and Treating Triple-Negative Breast Cancer
    Anders, Carey
    ONCOLOGY-NEW YORK, 2008, 22 (11): : 1233 - 1239
  • [6] Atezolizumab for metastatic triple-negative breast cancer
    Stirrups, Robert
    LANCET ONCOLOGY, 2018, 19 (10): : E519 - E519
  • [7] Iniparib in Metastatic Triple-Negative Breast Cancer
    Domagala, Pawel
    Lubinski, Jan
    Domagala, Wenancjusz
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (18): : 1780 - 1780
  • [8] Treatment of Metastatic Triple-Negative Breast Cancer
    Glendenning, Jennifer
    Irshad, Sheeba
    Tutt, Andrew
    CURRENT BREAST CANCER REPORTS, 2012, 4 (01) : 10 - 21
  • [9] Treatment of Metastatic Triple-Negative Breast Cancer
    Jennifer Glendenning
    Sheeba Irshad
    Andrew Tutt
    Current Breast Cancer Reports, 2012, 4 (1) : 10 - 21
  • [10] A systematic literature review on direct and indirect costs of triple-negative breast cancer
    Sadeq Rezaei
    Majid Babaei
    Cost Effectiveness and Resource Allocation, 21